Equities research analysts expect Voyager Therapeutics Inc (NASDAQ:VYGR) to report ($0.76) earnings per share for the current quarter, according to Zacks. Four analysts have made estimates for Voyager Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.46) and the lowest estimate coming in at ($0.91). Voyager Therapeutics reported earnings per share of ($0.89) during the same quarter last year, which suggests a positive year over year growth rate of 14.6%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 1st.
According to Zacks, analysts expect that Voyager Therapeutics will report full year earnings of ($3.12) per share for the current financial year, with EPS estimates ranging from ($3.41) to ($2.43). For the next year, analysts expect that the company will post earnings of ($3.39) per share, with EPS estimates ranging from ($4.29) to ($2.60). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.13). The company had revenue of $2.58 million for the quarter, compared to analyst estimates of $3.00 million. Voyager Therapeutics had a negative return on equity of 80.68% and a negative net margin of 731.88%.
VYGR has been the subject of several research reports. BidaskClub cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 20th. ValuEngine cut shares of Voyager Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, September 17th. HC Wainwright set a $30.00 price target on shares of Voyager Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 8th. Canaccord Genuity reiterated a “buy” rating and issued a $31.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, July 17th. Finally, Morgan Stanley cut shares of Voyager Therapeutics from an “overweight” rating to an “equal” rating in a research note on Monday, September 10th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $31.09.
In other Voyager Therapeutics news, Director Glenn Pierce purchased 5,000 shares of the stock in a transaction on Wednesday, September 12th. The shares were purchased at an average price of $18.44 per share, with a total value of $92,200.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director James A. Geraghty purchased 3,000 shares of the stock in a transaction on Friday, August 17th. The stock was acquired at an average cost of $18.31 per share, for a total transaction of $54,930.00. Following the acquisition, the director now directly owns 73,588 shares in the company, valued at $1,347,396.28. The disclosure for this purchase can be found here. Insiders acquired a total of 11,000 shares of company stock worth $205,300 in the last three months. Insiders own 33.60% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. MetLife Investment Advisors LLC boosted its stake in shares of Voyager Therapeutics by 38.6% in the 2nd quarter. MetLife Investment Advisors LLC now owns 10,649 shares of the company’s stock valued at $208,000 after purchasing an additional 2,964 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Voyager Therapeutics by 18.3% in the 2nd quarter. Rhumbline Advisers now owns 20,258 shares of the company’s stock valued at $396,000 after purchasing an additional 3,132 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of Voyager Therapeutics by 53.6% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $177,000 after purchasing an additional 3,157 shares in the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Voyager Therapeutics by 27.4% in the 2nd quarter. Commonwealth Equity Services LLC now owns 16,272 shares of the company’s stock valued at $318,000 after purchasing an additional 3,500 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of Voyager Therapeutics by 19.9% in the 1st quarter. Barclays PLC now owns 32,577 shares of the company’s stock valued at $612,000 after purchasing an additional 5,415 shares in the last quarter. 89.64% of the stock is currently owned by hedge funds and other institutional investors.
VYGR stock opened at $16.95 on Friday. The company has a market cap of $613.69 million, a P/E ratio of -6.42 and a beta of 2.94. Voyager Therapeutics has a 52 week low of $11.54 and a 52 week high of $31.91.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Featured Article: How to interpret a stock’s beta number
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.